{"id": "1267218693999792129", "in_reply_to_user_id": "3142088601", "author_id": "3234116877", "public_metrics": {"retweet_count": 0, "reply_count": 1, "like_count": 0, "quote_count": 0}, "referenced_tweets": [{"type": "replied_to", "id": "1267213582686736386"}], "created_at": "2020-05-31T22:17:35.000Z", "conversation_id": "1267212611315269633", "entities": {"mentions": [{"start": 0, "end": 12, "username": "BertrandBio", "id": "3142088601"}, {"start": 13, "end": 18, "username": "NCCN", "id": "757251422"}, {"start": 19, "end": 24, "username": "ASCO", "id": "20187065"}, {"start": 25, "end": 41, "username": "ConquerCancerFd", "id": "221775604"}, {"start": 42, "end": 54, "username": "peterbachmd", "id": "277191527"}]}, "source": "Twitter for iPhone", "reply_settings": "everyone", "text": "@BertrandBio @NCCN @ASCO @ConquerCancerFd @peterbachmd I don\u2019t think so, hard to study receipt of therapy if including patients who don\u2019t have the disease?", "possibly_sensitive": false, "lang": "en"}